Glioma Diagnosis and Treatment

ONC206 demonstrates potent anti-tumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma

This study shows ONC206 effectively kills medulloblastoma cells and extends survival in mouse models, supporting its potential as a new treatment for high-risk medulloblastoma.

The DDIT4L-TOM40-ATP5A pathway suppresses glioblastoma oncogenesis

This study identifies DDIT4L as an inhibitor of glioblastoma by suppressing mitochondrial function and inducing apoptosis, with a synthetic peptide showing therapeutic potential.

Disrupting Akt-Wnt/β-catenin signaling suppresses glioblastoma stem cell growth and tumor progression in immunocompetent mice

This study shows that inhibiting Akt with MK-2206 suppresses glioblastoma growth and progression in mice, outperforming a β-catenin inhibitor in vitro and in vivo.

TET CpG sequence context specific DNA demeth-ylation shapes progression of IDH-mutant gliomas

The paper identifies DNA methylation changes during IDH-mutant glioma progression, links them to TET enzyme activity, and develops a methylation-based grading system that outperforms WHO grading.

Innate Immune Receptor NLRX1: Potential Modulator of Glioblastoma Pathophysiology

This study shows NLRX1 modulates glioblastoma cell proliferation, migration, and metabolism by affecting autophagy and tunneling nanotubes.

Functionally distinct ALK and ROS1 fusions detected in infant-type hemispheric gliomas converge on STAT3 and SHP2 activation

The paper identifies functionally distinct ALK and ROS1 fusions in infant-type hemispheric gliomas, showing they converge on STAT3 and SHP2 activation through different mechanisms.

Spatially Integrated Multi-Omics reveals the Multicellular Landscape of Progenitor-Driven Glioblastoma Progression

This study integrates multi-omic data from glioblastoma patients to identify a high-risk progenitor phenotype linked to poor survival and spatially defined tumor progression.

Convergence on BRAF and MAPK Signaling in Glioma Development in a P53-ENU model

This study develops a mouse model of pediatric gliomas and identifies BRAF and MAPK signaling as critical drivers of tumor progression and therapeutic resistance.

Predictable clonal hierarchies from restricted progenitors provide a framework for cell type-specific therapies in glioblastoma

The paper maps clonal hierarchies in glioblastoma using lineage-resolved single-cell data, revealing multiple non-redundant progenitors and identifying cell type-specific therapeutic targets.

Disconnect between in vitro and in vivo efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma

This study evaluates the efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma in vitro and in vivo, finding strong in vitro activity but no antitumor effect in mouse models.

Evaluation of Significance of SERPINA3 and SPP1 in Driving Glioma Progression Through Dysregulation of Brain Inflammatory Pathway

The paper evaluates SERPINA3 and SPP1 as potential biomarkers for glioma progression by analyzing their expression and functional relevance in the tumour microenvironment.

A Systems approach identifies MERTK as a therapeutic vulnerability in ZFTA-RELA-driven ependymomas

This study identifies MERTK as a therapeutic target in ZFTA-RELA-driven ependymomas through transcriptomic analysis and drug screening.

Pharmacological induction of mitochondrial stress counteracts therapy resistance in glioblastoma stem-like cells

This study shows that doxycycline induces mitochondrial stress and selectively kills glioblastoma stem-like cells, offering a drug repurposing strategy for therapy-resistant gliomas.

IDH-mutant inhibitors enhance the sensitivity of IDH1-mutant gliomas to cysteine-methionine deprivation and ferroptosis

This study shows that IDH1-mutant glioma cells are more sensitive to cysteine-methionine deprivation and ferroptosis inducers, and that IDH inhibitors enhance this sensitivity.

SOX21 Suppresses Glioblastoma Growth by Repressing AP-1 Activity

This study shows SOX21 suppresses glioblastoma stem cells by repressing AP-1 activity, leading to reduced tumor growth and improved survival in mouse models.

Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma

This paper evaluates the combination of B7-H3 CAR T cells and ONC206 against DIPG models, showing enhanced anti-tumor efficacy in vitro and in vivo.

Distinct tumor immune microenvironmental (TIME) landscapes drive divergent immunotherapy responses in glioblastoma

This study identifies three distinct tumor immune microenvironment (TIME) subtypes in glioblastoma (GBM) with divergent responses to immunotherapy, supporting personalized treatment strategies.

Spatial pharmaco-multiomics reveals drug distribution, metabolic niches, and spatially constrained resistance in medulloblastoma

This study develops a spatial pharmaco-multiomics framework to map drug distribution, metabolic niches, and resistance mechanisms in medulloblastoma using integrated spatial and transcriptomic data.

Cancer-myeloid cell invasive program in pediatric-type diffuse high-grade glioma

This paper presents an integrative multimodal atlas of pediatric-type diffuse high-grade gliomas, identifying cancer-myeloid cell programs and distinct cancer cell states across multiple patients.

Accurate identification of medulloblastoma subtypes from diverse data sources with severe batch effects by RaMBat

RaMBat accurately identifies medulloblastoma subtypes from diverse data sources with severe batch effects, achieving 99% median accuracy.

Identification of an epigenetically and phenotypically distinct peritumoral glioblastoma cell population linked to inferior patient outcome

The paper identifies a distinct peritumoral glioblastoma cell population with unique epigenetic and phenotypic features associated with poor patient outcomes.

Critical role of cell competition in gliomagenesis

This study identifies cell competition as a key driver of gliomagenesis by showing that pre-malignant OPCs outcompete wildtype cells, and inhibiting this process reduces tumor growth.

Subtype-Specific SASP Dynamics Predict Mesenchymal Transition in Recurrent Glioblastoma

The paper tracks SASP dynamics in glioblastoma recurrence and finds subtype-specific patterns linked to mesenchymal transition and poor prognosis.

Microenvironment-Inferred Genotyping: An Exclusionary Classifier for EGFR Amplification When DNA Testing Fails

This paper develops a classifier to infer EGFR amplification from RNA-seq data when DNA testing is unavailable, achieving high accuracy in glioblastoma patients.

MIF-mediated reprogramming of myeloid lineage within the glioma tumor microenvironment impacts the efficacy of immune stimulatory gene therapy

This study identifies MIF-CD74 axis regulation of myeloid cells in gliomas and shows that MIF inhibition enhances immune therapy efficacy in wtIDH1 gliomas.

CD276 (B7-H3) as a Companion Diagnostic Biomarker for Glioblastoma: Multi-Platform Validation and Therapeutic Implications

This paper validates CD276 as a prognostic biomarker for glioblastoma across multiple platforms and identifies its therapeutic implications for ADC therapy.

IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation

This study identifies glial progenitor cells as the cell-of-origin for IDH-mutant gliomas by analyzing patient tissues and mouse models.

Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations

The paper integrates single-cell RNA sequencing data with drug response signatures to identify drug-sensitive and resistant glioblastoma cell states and predict synergistic drug combinations.

THOC1 complexes with SIN3A to regulate R-loops and promote glioblastoma progression

This study identifies THOC1 as a driver of glioblastoma progression by interacting with SIN3A to regulate R-loops and telomere stability.

De novo H3.3K27M-altered Diffuse Midline Glioma in human brainstem organoids to dissect GD2 CAR T cell function

This paper develops a human brainstem organoid model of H3.3K27M-altered DMG to study GD2 CAR T cell function and identify therapeutic targets.